Nemluvio

How Does Nemluvio Work?

Nemluvio works by blocking the IL-31 receptor alpha (IL-31RA) on the surface of cells in the skin and nervous system. IL-31 is a naturally occurring cytokine that functions as the primary "itch cytokine" — it binds to receptors on sensory nerve fibers and triggers the brain's itch response. In prurigo nodularis and atopic dermatitis, IL-31 is overproduced, driving relentless, chronic itch and a cycle of scratching that worsens the skin.

By selectively binding to IL-31RA, Nemluvio prevents IL-31 from attaching to its receptor and initiating the itch signal. This targeted block has downstream effects: it reduces pruritus (itch), decreases skin inflammation, improves epidermal barrier function, and reduces the fibrosis (hardening) that characterizes prurigo nodularis nodules over time.

Because Nemluvio acts through subcutaneous injection and is absorbed into the bloodstream, it reaches skin tissue systemically. Its terminal elimination half-life is approximately 18.9 days, supporting a once-monthly dosing schedule that many patients find more convenient than the every-two-week schedule of Dupixent (dupilumab).

How Hard Is It to Find Nemluvio in Stock?

Nemluvio is not in shortage as of 2026 — it is not listed on the FDA's drug shortage database, and Galderma reports stable supply through its specialty pharmacy network. However, patients routinely encounter difficulty finding or obtaining Nemluvio because it is exclusively distributed through specialty pharmacies, not retail chains like CVS or Walgreens.

The barriers to access are primarily administrative: prior authorization requirements from insurance companies, the need to enroll in the GPS (Galderma Patient Services) specialty pharmacy program, and the relatively new status of the drug (approved in late 2024) means some insurance formularies are still catching up. Nemluvio is a moderate-findability medication — not a shortage drug, but not easily picked up at your corner pharmacy either.

If you're having difficulty getting Nemluvio filled, medfinder can call specialty pharmacies on your behalf to identify which ones can fill your prescription, cutting down on frustrating phone calls and delays.

Who Can Prescribe Nemluvio?

Nemluvio is not a controlled substance and has no DEA scheduling restrictions. Any licensed prescriber can technically write a prescription. However, in practice, Nemluvio is almost exclusively prescribed by specialists due to the complex diagnostic and documentation requirements for prior authorization.

Dermatologists — primary prescribers for both prurigo nodularis and atopic dermatitis

Allergists and Immunologists — may prescribe for atopic dermatitis patients with concurrent allergic conditions

Nurse Practitioners (NP) and Physician Assistants (PA) — in dermatology or allergy practices with prescriptive authority

Telehealth dermatology options exist for established patients, particularly those seeking Nemluvio prescription renewals for atopic dermatitis. First-time prurigo nodularis diagnoses typically require in-person examination of the skin nodules. Telehealth platforms including dedicated dermatology services can connect patients with licensed prescribers remotely.

Is Nemluvio a Controlled Substance?

No. Nemluvio (nemolizumab-ilto) is not a controlled substance and has no DEA schedule. It does not require a special DEA prescription form, and there are no restrictions on the number of refills based on controlled substance scheduling.

While Nemluvio does not have DEA restrictions, it is a prescription-only medication that requires a valid prescription from a licensed healthcare provider. Because it is a specialty biologic, all prescriptions must be channeled through the GPS for Nemluvio enrollment process and dispensed by specialty pharmacies — but this is a logistical requirement, not a controlled substance requirement.

Common Side Effects of Nemluvio

Nemluvio has a favorable safety profile with no FDA boxed warnings. Common side effects (occurring in ≥1% of clinical trial patients):

Headache

Atopic dermatitis or eczema flares (in PN patients)

Nummular eczema (round, coin-shaped patches of itchy rash)

Injection site reactions (redness, swelling, discomfort at injection site)

Muscle and joint pain (myalgia, arthralgia)

Serious Side Effects

Hypersensitivity reactions (including facial angioedema) — rare but potentially serious. Stop Nemluvio and seek emergency care if you experience swelling of the face, lips, tongue, or throat, difficulty breathing, or severe hives.

Final Thoughts on Nemluvio

Nemluvio represents a significant advance in the treatment of prurigo nodularis and atopic dermatitis. As the first IL-31 receptor antagonist approved by the FDA, it fills a critical gap for patients who haven't found adequate relief with topical therapies or other biologics. Its monthly dosing schedule and favorable safety profile (no boxed warnings) make it a compelling option for appropriate patients.

The primary barrier to Nemluvio is access — not supply. Prior authorization requirements, specialty pharmacy enrollment, and insurance formulary gaps can delay treatment. Patients who understand the GPS for Nemluvio support programs (Quick Start, Copay Assistance, Bridge, and Patient Assistance) are far better positioned to navigate these barriers. For those without insurance, the Patient Assistance Program may provide medication at no cost.

If you're struggling to find Nemluvio at a pharmacy or navigate specialty pharmacy access, medfinder can help. We call pharmacies near you to identify which ones can fill your prescription, and we text you the results — so you can focus on your health rather than spending hours on hold.